Full notification file
Member State to which the notification was sent
Date of acknowledgement from the Member State Competent Authority
Title of the Project
Phase I/IIa AdCD40L immunogene therapy for malignant melanoma in patients with disseminated disease
Proposed period of release:
01/05/2011 to 31/05/2013
Name of the Institute(s) or Company(ies)
Uppsala University, Department of Immunology, Genetics and Pathology, Uppsala, Sweden.;
3. Is the same GMO release planned elsewhere in the Community?
Has the same GMO been notified elsewhere by the same notifier?
If yes, notification number(s):
GMO is a:
Identity of the GMO:
AdCD40L is consisting of a recombinant adenovirus group C serotype 5 E1E3 deleted vector expressing the human CD40L (CD154) gene under controll of a promoter derived from Rous Sarcoma Virus (RSV) (Leimig et al Human Gene Ther 7:1233-1239, 1996; Takahashi et al Hum Gene Ther 12:659-670, 2001).
Information relating to the recipient or parental organisms from wich the GMO is derived
Adenovirus human serotype 5 (Ad5)
European Commission administrative information
Consent given by the Member State Competent Authority: